文献速递血管炎其他结缔组织病

儿童白塞病的生物制剂治疗:PRES血管炎工作组国际协作研究结果

Biological therapies in paediatric Behçet's disease: results of an international collaborative study by the PRES Vasculitis Working Party.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

这项多中心回顾性研究分析了来自6个国家19个中心的109例儿童白塞病患者,其中土耳其64例、欧洲45例,主要生物制剂启动指征为眼部(40.4%)、黏膜皮肤(22.9%)和神经系统(17.4%)受累;TNF-α抑制剂使用率90.8%,阿达木单抗59例、英夫利西单抗38例;两种药物缓解率相似,阿达木单抗组疾病活动度评分下降更快但差异无统计学意义(P=0.2);仅报告1例严重感染,未观察到恶性肿瘤或自身免疫病。

要点

  • 眼部、黏膜皮肤和神经系统受累是儿童白塞病启动生物制剂的主要指征。
  • TNF-α抑制剂使用率90.8%,以阿达木单抗(59例)和英夫利西单抗(38例)为主。
  • 阿达木单抗与英夫利西单抗缓解率相似,仅报告1例严重感染,未观察到恶性肿瘤或自身免疫病。

核心结论

  • 生物制剂在儿童白塞病中表现出稳健的疗效和可接受的安全性。
  • 研究强调眼部、黏膜皮肤和神经系统受累是启动生物制剂的主要指征,并提供了区域治疗策略的见解。

研究设计与样本

  • 多中心回顾性研究,纳入来自儿科风湿病欧洲学会(PRES)血管炎研究组的109例18岁前诊断为儿童白塞病的患者,涉及6个国家19个中心。
  • 患者中64例来自土耳其,45例来自欧洲。

主要发现

  • 启动生物制剂的主要指征为眼部受累(40.4%)、黏膜皮肤受累(22.9%)和神经系统受累(17.4%)。
  • TNF-α抑制剂用于90.8%的病例,最常用药物为阿达木单抗(59例)和英夫利西单抗(38例)。
  • 土耳其队列皮肤受累较欧洲队列更常见(P < 0.01),其他器官/系统受累相似。
  • 欧洲组从症状出现到诊断的间隔更长;生物制剂启动更早且持续时间更长,但差异无统计学意义。
  • 接受阿达木单抗和英夫利西单抗的患者缓解率相似;接受阿达木单抗的患者疾病活动度评分下降更快,但差异无统计学意义(P = 0.2)。

关键数值与推荐

  • 生物制剂启动指征:眼部受累40.4%、黏膜皮肤受累22.9%、神经系统受累17.4%。
  • TNF-α抑制剂使用率90.8%,其中阿达木单抗59例、英夫利西单抗38例。
  • 土耳其队列与欧洲队列皮肤受累比较P < 0.01。
  • 阿达木单抗与英夫利西单抗疾病活动度评分下降速度比较P = 0.2,差异无统计学意义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to examine the indications for paediatric rheumatologists to use biologic therapies in childhood Behçet's disease (BD), as well as the efficacy, safety and remission rates of such treatments. We also compare demographic and clinical characteristics of Turkish and European cohorts. METHODS: In this multicentric retrospective study, the data of 109 paediatric BD (pedBD) patients diagnosed before 18 years of age, obtained from Pediatric Rheumatology European Society (PRES) vasculitis study group, which involves 19 centres across six countries were analysed. RESULTS: Of the patients, 64 were from Turkey and 45 from Europe. The primary indications for initiating biologics were ocular (40.4%), mucocutaneous (22.9%) and neurologic (17.4%) involvement. TNF-α inhibitors were used in 90.8% of cases, with adalimumab (ADA, 59 patients) and infliximab (IFX, 38 patients) being the most commonly prescribed agents. Skin involvement was more common in Turkish cohort compared with European cohort (P < 0.01), while other organ/system involvement was similar. The interval between symptom onset and diagnosis was longer in the European group. Though not significant, biological therapies were initiated earlier and had longer duration in the European cohort. Remission rates were similar in patients receiving ADA and IFX; however, patients receiving ADA experienced a faster decline in disease activity scores, but the difference was not significant (P = 0.2). Only one serious infection was reported, and no malignancy/autoimmune disease were observed. CONCLUSION: Biologic therapies exhibit robust efficacy and an acceptable safety profile in pedBD. The study emphasizes ocular, mucocutaneous and neurological involvement as principal indications for initiating biologics and offers regional insights into therapeutic strategies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Akgün Ö, Demirkan FG, Koné-Paut I, et al. Biological therapies in paediatric Behçet's disease: results of an international collaborative study by the PRES Vasculitis Working Party. Rheumatology (Oxford). 2026. PMID: 40748718. doi:10.1093/rheumatology/keaf404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。